ticlopidine has been researched along with Aortic Valve Insufficiency in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Aortic Valve Insufficiency: Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mean aortic regurgitation grade was unchanged." | 2.72 | Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. ( Buellesfeld, L; Felderhoff, T; Gerckens, U; Grube, E; Iversen, S; Laborde, JC; Menichelli, M; Mueller, R; Sauren, B; Schmidt, T; Stone, GW; Zickmann, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grube, E | 1 |
| Laborde, JC | 1 |
| Gerckens, U | 1 |
| Felderhoff, T | 1 |
| Sauren, B | 1 |
| Buellesfeld, L | 1 |
| Mueller, R | 1 |
| Menichelli, M | 1 |
| Schmidt, T | 1 |
| Zickmann, B | 1 |
| Iversen, S | 1 |
| Stone, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CoreValve® System Australia/New Zealand Clinical Study[NCT01015612] | 634 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
is defined per Valve Academic Research Consortium-1 consensus document (VARC-1), including Cardiovascular and non-cardiovascular mortality. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.038 |
Defined as all death resulting from a cardiac cause or complications of a cardiac procedure and / or death of an unknown cause; this category includes valve-related deaths and non-valve-related cardiac deaths (e.g. congestive heart failure, acute myocardial infarction, documented fatal arrhythmias). (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.035 |
Defined as a composite of all cause death, myocardial infarction(MI) (Q-wave & non-Q-wave), stroke, and re-intervention (defined as any emergent cardiac surgery or percutaneous re-intervention catheter procedure that repairs, otherwise alters or adjusts or replaces a previously implanted valve) (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.099 |
Included Q-wave and non-Q-wave. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.021 |
"Vascular access, delivery and deployment of the device, and retrieval of the delivery system~Correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function)~Intended performance of the prosthetic valve (aortic valve area > 1.2 cm2 (by echocardiography using the continuity equation) and mean aortic valve gradient < 20 mmHg, without moderate or severe prosthetic valve aortic regurgitation)~Only one valve implanted~No occurrence of in-hospital MACCE" (NCT01015612)
Timeframe: 24-48 hours after the procedure or before the discharge
| Intervention | % of participants with device success (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 52.6 |
Any emergent surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.019 |
Is a neurological deficit lasting more than 24 hours, or lasting 24 hours or less with a brain imaging study showing infarction. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.043 |
1 trial available for ticlopidine and Aortic Valve Insufficiency
| Article | Year |
|---|---|
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Bioprosthe | 2006 |